Study identifier:D3250L00046
ClinicalTrials.gov identifier:NCT06465485
EudraCT identifier:N/A
CTIS identifier:N/A
STEP: A Prospective, Interventional, Multicenter, Single-Arm Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients with Severe Eosinophilic Asthma Treated with Benralizumab
Severe Eosinophilic Asthma
Phase 3
No
Benralizumab
All
500
Interventional
12 Years - 75 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Benralizumab Severe eosinophilic asthma taking medium-high dose ICS/LABA with/without LTRAs, LAMAs will be all treated by study Drug. | - |